(PharmaNewsWire.Com, October 08, 2018 ) Marburg hemorrhagic fever is a rare, acute infectious which affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain and weight loss.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever)-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 12 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.
Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
-The pipeline guide provides a snapshot of the global therapeutic landscape of Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease). -The pipeline guide reviews pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. -The pipeline guide reviews key companies involved in Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects. -The pipeline guide evaluates Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. -The pipeline guide encapsulates all the dormant and discontinued pipeline projects. -The pipeline guide reviews latest news related to pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease)
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: